| Prev Close: | 28.89 |
|---|
| Open: | N/A |
|---|
| Bid: | 28.40 x 500 |
|---|
| Ask: | 29.10 x 500 |
|---|
| 1y Target Est: | 31.72 |
|---|
| Beta: | 0.81 |
|---|
| Next Earnings Date: | 29-Oct-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 23.55 - 31.15 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 27,228,100 |
|---|
| Market Cap: | 191.26B |
|---|
| P/E (ttm): | 8.02 |
|---|
| EPS (ttm): | 3.60 |
|---|
| Div & Yield: | 0.96 (3.30%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Featured on Yahoo! Finance
Headlines
- F.D.A. Bans Three Arsenic Drugs Used in Poultry and Pig Feedsat New York Times(Tue, Oct 1)
- Final Glance: Pharmaceuticals companiesAP(Tue, Oct 1)
- Apple Now Holds 10% of All Corporate Cash: Moody'sat The Wall Street Journal(Tue, Oct 1)
- Does Lexicon Own the Future of Type 2 Diabetes?at Motley Fool(Tue, Oct 1)
- Top-line Data on Astellas' IsavuconazoleZacks(Tue, Oct 1)
- Merck’s Big Bet on R&D Founders, and 8,500 Job Cuts Ensueat BusinessWeek(Tue, Oct 1)
- No Shutdown for the Markets as the Dow Runs Higherat Motley Fool(Tue, Oct 1)
- Merck rises after announcing major restructuringat theflyonthewall.com(Tue, Oct 1)
- Earnings Outliers: The Real Deal on Corporate Profitabilityat BusinessWeek(Tue, Oct 1)
- Merck to slash annual costs by $2.5 billion, cut 8,500 jobsReuters(Tue, Oct 1)
- Merck to slash annual costs by $2.5 bln, cut 8,500 jobsReuters(Tue, Oct 1)
- Candy Crush IPO Needs a Better Innovation Planat BusinessWeek(Tue, Oct 1)
- Midday Glance: Pharmaceuticals companiesAP(Tue, Oct 1)
- Merck Restructuring Plan To Save $2.5 Bil Lifts Stockat Investor's Business Daily(Tue, Oct 1)
- Merck Cuts 8,500 Jobs, Amazon Hires 70,000 For Holiday Season As BLS Suspends Jobs Reportat Forbes(Tue, Oct 1)
Key Statistics
| Forward P/E (1 yr): | 12.56 |
|---|
| P/S (ttm): | 3.38 |
|---|
| Ex-Dividend Date: | 31-Jul-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 2.16 |
|---|
| Quarterly EPS Est
(Sep-13)
: | 0.56 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 4.59 |
|---|
Business Summary
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Its Primary Care segment offers human prescription pharmaceutical products primarily prescribed by primary-care phys...
View More